Aerie Pharmaceuticals (NASDAQ:AERI) received a $85.00 price objective from equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday, February 26th. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 81.55% from the company’s current price.
Several other analysts have also issued reports on AERI. Mizuho reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, February 8th. ValuEngine lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. Oppenheimer began coverage on Aerie Pharmaceuticals in a research note on Monday, December 3rd. They issued a “buy” rating and a $64.00 price objective on the stock. BidaskClub lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 10th. Finally, FIX began coverage on Aerie Pharmaceuticals in a research note on Monday, November 12th. They issued a “reduce” rating and a $64.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $77.17.
Shares of AERI stock traded down $2.43 on Tuesday, hitting $46.82. 655,826 shares of the stock were exchanged, compared to its average volume of 877,618. The stock has a market capitalization of $2.13 billion, a P/E ratio of -10.07 and a beta of 0.97. Aerie Pharmaceuticals has a fifty-two week low of $32.18 and a fifty-two week high of $74.75.
In other news, insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $35.21, for a total transaction of $387,310.00. Following the transaction, the insider now owns 106,743 shares in the company, valued at $3,758,421.03. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 10.53% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can increased its stake in shares of Aerie Pharmaceuticals by 40.2% during the fourth quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock worth $38,000 after purchasing an additional 304 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Aerie Pharmaceuticals by 23.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $99,000 after buying an additional 515 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in Aerie Pharmaceuticals by 3.6% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 19,031 shares of the company’s stock worth $687,000 after buying an additional 660 shares in the last quarter. Chartwell Investment Partners LLC grew its position in Aerie Pharmaceuticals by 3.2% during the fourth quarter. Chartwell Investment Partners LLC now owns 23,735 shares of the company’s stock worth $857,000 after buying an additional 734 shares in the last quarter. Finally, Teachers Advisors LLC grew its position in Aerie Pharmaceuticals by 1.1% during the third quarter. Teachers Advisors LLC now owns 70,937 shares of the company’s stock worth $4,366,000 after buying an additional 772 shares in the last quarter.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Read More: How to interpret a stock’s beta number
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.